dtg

Listen to Roger Bedimo, MD, MS, FACP, discuss considerations for older people living with HIV, including:

• Polypharmacy and deprescribing
• The risk of cardiovascular events with various ART regimens
• Approaches for managing weight gain

Presenter:

Roger Bedimo, MD, MS, FACP
Professor of Medicine
Interim Director, Office of Global Health
UT Southwestern Medical Center
Chief, Infectious Diseases Section
VA North Texas Health Care System
Dallas, Texas

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

To download the slides: 
 https://bit.ly/49zrnZs

To view the full online program:
https://bit.ly/49x0W6D

In this podcast episode, Isolde Butler, MD, MPH, a healthcare professional caring for people living with HIV, and Marissa Gonzalez, an individual living with HIV, discuss strategies to improve healthcare professionals’ competencies in delivering optimal HIV care from the start to better support patients in overcoming barriers to sustained care engagement.

The topics they discuss include: 

• An introduction to the guidelines on ART initiation—start quickly and choose the therapy that is effective and tolerable
• The patient experience, from initial diagnosis to treatment selection, noting that where people get diagnosed matters in determining the level of support they will receive
• The complete HIV care team: healthcare professionals, navigators, case managers, behavioral health providers, mental health providers, and so on. Smaller clinics may not be able to provide adequate support to meet all patient needs
• How to navigate the first visit after an HIV diagnosis, including patient–provider treatment discussions on the available therapies that can help with stigma
• HIV stigma education; navigating the miseducation and misinformation

Presenters:

Isolde F. Butler, MD, MPH
Chief Medical Officer
Cresentcare
New Orleans, Louisiana

Marissa Gonzalez
Chair
Community Advisory Board
The Well Project

Link to full program:
https://bit.ly/3TqVnl1

In this episode, Renslow Sherer, MD, discusses managing virologic failure in a person living with HIV who is heavily treatment experienced, including:

• Guideline recommendations for selecting a new ART regimen
• Options for patients with multidrug-resistant HIV from existing drug classes and novel mechanisms of action with no cross-resistance
• Data from TMB-301 and TMB-311 for ibalizumab, BRIGHTE for fostemsavir, and CAPELLA for lenacapavir on the use of these agents for people living with HIV who are heavily treatment experienced with multidrug-resistant HIV

Presenter:

Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois

To download the slides:
https://bit.ly/3OcqxIE

To view the full online program:
https://bit.ly/3ZjSFhg

In this episode, Daniel R. Kuritzkes, MD, and Cristina Mussini, MD, discuss managing ART failure, including:

• The definitions of virologic blips, low-level viremia, and virologic failure on ART
• The infrequency of failure with resistance on first-line INSTI-based ART and the instances where this has occurred with BIC- and DTG-based ART in clinical trials and in the real world
• The potential reasons for ART failure, including patient/adherence-related factors, HIV-related factors, and regimen-related factors
• The impact of adherence on viral suppression with BIC- and DTG-based ART
• Drug-drug interactions as a reason for failure of first-line INSTI-based ART
• What to do if someone is experiencing virologic failure requiring an ART change
• The use of proviral DNA testing in patients with viral suppression or low-level viremia with ART treatment experience
• The impact of high HIV-1 RNA on ART effectiveness
• The impact of NRTI resistance, including the M184V and K65R mutations, on the effectiveness of BIC- and DTG-based ART
• Strategies to encourage and measure patient adherence to ART 

Presenters

Daniel R. Kuritzkes, MD
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Boston, Massachusetts

Cristina Mussini, MD
Professor
Department of Infectious Diseases
University of Modena and 
Reggio Emilia
Modena, Italy

Link to full program: https://bit.ly/3HPu4Lk

In this episode, Renslow Sherer, MD, discusses managing a first ART failure in the setting of COVID-19, including:

• Guideline recommendations for resistance testing
• Guideline recommendations for selecting a new ART regimen
• Data on retained efficacy of NRTIs in second-line regimens in the EARNEST and NADIA studies
• Consideration of drug‒drug interactions between ART and COVID-19 treatment

Presenter: 
Renslow Sherer, MD
Director 
International HIV Training Center 
Professor of Medicine 
Section of Infectious Diseases and Global Health 
Department of Medicine 
University of Chicago 
Chicago, Illinois 

To download the slides: https://bit.ly/3OcqxIE 

To view the full online program: https://bit.ly/3ZjSFhg

In this episode, Maunank Shah, MD, PhD, discusses using HIV-ASSIST to optimize treatment for both HIV and hyperlipidemia. Listen as he covers:

• Hyperlipidemia and cardiovascular disease risk among people living with HIV
• Recommendations for lipid screening for people living with HIV
• Using HIV-ASSIST to support ART treatment decisions for people living with HIV with comorbidities
• How HIV-ASSIST prioritizes certain ART agents in the setting of hyperlipidemia, including:
  • Deciding between bictegravir, doravirine, dolutegravir, raltegravir, and rilpivirine vs boosted protease inhibitors, including darunavir
  • Deciding between tenofovir disoproxil fumarate and tenofovir alafenamide or abacavir
• How HIV-ASSIST incorporates drug‒drug interaction data from the University of Liverpool HIV Drug Interactions Checker and the DHHS guidelines when considering the use of statin therapy with ART
• How HIV-ASSIST further incorporates drug resistance data from the Stanford HIV Drug Resistance Database

Maunank Shah, MD, PhD 
Associate Professor 
Infectious Diseases 
Johns Hopkins University 
Baltimore, Maryland 

Link to full program: bit.ly/3pwaH2Y

In this episode, Marta Boffito, MD, PhD, FRCP, and Michelle Cespedes, MD, MS, discuss initial ART options, including:

• Recommended first-line ART options for most PWH according to DHHS, IAS-USA, EACS, BHIVA, and WHO guidelines 
• Data for weight gain after ART initiation with different ARV classes and drugs
• Weight gain disparities by race and gender after ART initiation
• Data from the RESPOND study including risk factors for weight gain and CV event risk with INSTI vs non-INSTI–based ART 
• The impact of INSTIs on CV events in the Swiss HIV Cohort study 
• Recommendations for ART and contraception for PWH of childbearing potential 
• Drug–drug interactions between first-line ART and contraceptive options 
• Guideline-recommended first-line ART options in pregnancy with a discussion of how these regimens differ from those recommended for most PWH 

Marta Boffito, MD, PhD, FRCP 
Consultant Physician 
Clinical Director, HIV, Sexual and Gender Health, Dermatology 
Chelsea and Westminster Hospital NHS Foundation Trust 
Imperial College London 
London, United Kingdom 

Michelle Cespedes, MD, MS 
Professor of Medicine 
Division of Infectious Disease 
Department of Medicine 
Icahn School of Medicine at 
Mount Sinai 
New York, New York 

Link to full program: bit.ly/3HPu4Lk

In this episode, Sonya Krishnan, MD, MHS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for a virologically suppressed PWH who is planning a pregnancy. Listen as she covers:

• How to input patient specific factors into the HIV-ASSIST tool
• Discussion of available education sheets to review the data and recommendations for her current ART regimen in pregnancy
• An explanation of why some regimens are ranked lower because of adherence factors such as increased pill burden or dosing frequency
• Guidelines informing the HIV-ASSIST output, including DHHS and IAS-USA, and the frequency with which updates are incorporated
• How to use the HIV-ASSIST output to guide regimen selection in pregnancy
• Use of the HIV-ASSIST tool in shared decision-making and patient counseling

Sonya Krishnan, MD, MHS
Assistant Professor
Division of Infectious Diseases
Johns Hopkins University
Baltimore, Maryland

Link to full program: 
bit.ly/3pwaH2Y

In this episode, Daniel R. Kuritzkes, MD, discusses considerations for patients experiencing weight gain on antiretroviral therapy, including:

• Commonly implicated antiretroviral therapy regimens and patient populations

• Guideline recommendations for management of weight gain

Presenter:

Daniel R. Kuritzkes, MD
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Boston, Massachusetts

To download the slides: 
bit.ly/3odUA9C

To view the full online program: 
bit.ly/3ZjSFhg

In this episode, Isolde Butler, MD, and Brenda E. Crabtree Ramírez, MD, discuss rapid ART initiation for people newly diagnosed with HIV, including:

• The HIV care continuum in the United States and Latin America
• Barriers to HIV diagnosis, including stigma, discriminatory laws and policies, social determinants of health, and lack of access to healthcare
• Factors that predict delayed care linkage and inconsistent HIV care and treatment
• Improved clinical outcomes that have been shown with rapid ART initiation, first in low- and middle-income countries and now worldwide
• Recommendations for rapid ART—and regimen choices—from the DHHS, IAS-USA, CENSIDA, EACS, and WHO
• Recommendations for transitioning from PrEP to ART when someone seroconverts while receiving either oral PrEP or LA CAB for PrEP
• Barriers to rapid ART initiation in their individual care settings
• The future of LA injectable ART for initial treatment and rapid initiation

Isolde Butler, MD
Chief Medical Officer
CrescentCare
New Orleans, Louisiana

Brenda E. Crabtree Ramírez, MD
Assistant Professor, HIV Program
Department of Infectious Diseases
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán
Mexico City, Mexico

Link to full program: bit.ly/3HPu4Lk

 In this episode, 2 Australian HIV experts share their thoughts on some of the most important HIV insights gained during the past year in the context of HIV care in Australia.

Specifically, the faculty discuss the continued dominance of second-generation INSTI-based regimens as mainstay HIV therapy in Australia, including in both 2-drug and 3-drug oral regimens; the emergence of 2-drug long-acting injectable therapy as a switch strategy; key aspects of successfully expanded oral PrEP programs in the region; the potential role of long-acting injectable PrEP; and key new advances in HIV cure research.  

Presenters:

Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
University of Melbourne  
Consultant Infectious Diseases Physician
Alfred Hospital and Royal Melbourne Hospital  
Melbourne, Australia

Don Smith, MD
Conjoint Professor
School of Population Medicine
University of New South Wales
Senior Staff Specialist
Albion Centre
South Eastern Sydney Local Health Network
Sydney, Australia

Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.  

Link to full program:
http://bit.ly/3YD8T4E

In this episode, Canadian HIV experts share their thoughts on some of the most important new insights from HIV treatment and prevention research over the past year.

Specifically, the faculty discuss treatment strategies for patients with a history of NRTI resistance based on findings from the 2SD and NADIA trials; the latest data informing the use of 2-drug oral and injectable treatment regimens; prevention approaches for HIV and other sexually transmitted infections based on findings from the DoxyPEP, HPTN 083, and HPTN 084 trials; and other emerging innovations in HIV care.

Presenters:
Jean-Guy Baril, MD
Associate Professor
Family Medicine
Université de Montreal
Montreal, Quebec, Canada

Alexander Wong MD, FRCPC
Associate Professor
Department of Medicine
University of Saskatchewan
Regina, Saskatchewan, Canada

Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.  

Link to full program:
http://bit.ly/3YD8T4E

In this episode, 2 European HIV experts share their thoughts on some of the most important new antiretroviral therapy insights from HIV research over the past year.

Specifically, the faculty discuss findings from real-world and long-term studies of 2-drug oral regimens, the latest on 2-drug long-acting injectable therapy, how 2-drug options fit into rapid start strategies, and other new and emerging innovations in HIV treatment, including the availability of lenacapavir for multidrug-resistant HIV treatment and resumption of islatravir clinical development.

Presenters:

Jürgen K. Rockstroh, MD
Professor of Medicine
University Hospital Bonn
Department of Medicine I
Bonn, Germany

Alexandra Calmy, MD, FMH, PhD
HIV/AIDS Unit Director
Infectious Diseases Division
Geneva University Hospitals
University of Geneva
Geneva, Switzerland

Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. andViiV Healthcare.

Link to full program:
http://bit.ly/3Hz0jNa

In this episode, Princy N. Kumar, MD, FIDSA, MACP, discusses key considerations for selecting ART in treatment-naive persons with HIV. Her discussion includes a review of the following studies on ART and weight gain:

• ADVANCE: men vs women receiving DTG + FTC/TAF, DTG + FTC/TDF, and EFV + FTC/TDF
• Comparison of ART regimens (eg, INSTI-, NNRTI- and PI-based regimens) in a pooled analysis of 8 phase III randomized controlled trials
• GEMINI-1 and GEMINI-2: DTG + 3TC vs DTG + FTC/TDF

Presenter:
Princy N. Kumar, MD, FIDSA, MACP
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.

Link to full program:
https://bit.ly/3VIsDTg

Follow along with the slides:
https://bit.ly/3PYy1zn

In this episode, Annette Haberl, MD, and William R. Short, MD, MPH, AAHIVS, discuss when to consider an ART switch during pregnancy, including:

• Current DHHS, EACS, WHO, BHIVA, and German/Austrian guidelines for the use of ARVs in pregnancy
• What data and recommendations for the use of ARVs during pregnancy are currently missing from the guidelines
• Available data on newer ARVs in the ARV pregnancy registry
• Pharmacokinetic data for newer ARVs including BIC/FTC/TAF and LA CAB + RPV in pregnancy
• Recommendations for 2-drug ART regimens in pregnancy
• What to do when someone becomes pregnant on a newer ART regimen that is not yet recommended by the guidelines

Annette Haberl, MD
Physician
Head of HIV and Women
HIVCENTER Frankfurt
Department of Infectious Disease
Hospital of the Johann Wolfgang Goethe University
Frankfurt, Germany

William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Link to full program:
https://bit.ly/3HPu4Lk

In this episode, Tristan J. Barber, MA, MD, FRCP, and Darcy Wooten, MD, discuss switching ART with virologic suppression, including:

• Switching with prior or unknown resistance
  • Data on switching to BIC/FTC/TAF with a preexisting M184V/I mutation from a pooled analysis of 6 phase III studies
  • The impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWH from the BRAAVE 2020 study
  • A post hoc analysis of the SALSA study of DTG/3TC outcomes at Week 48 by baseline resistance
  • Data from the SOLAR 3D study on switching to DTG/3TC from a 3- or 4-drug ART regimen with a history of M184V
  • A retrospective analysis of switching to DTG/3TC with archived M184V/I from the French Dat’AIDS Cohort
• Switching to long-acting ART
  • Guidance on candidates for LA CAB + RPV
  • Data on risk factors for virologic failure with LA CAB + RPV
• Considering an ART switch after weight gain
  • Data on weight gain after ART initiation by ARV class and drug
  • Mean change in weight by sex at Week 96 in the ADVANCE study
  • DHHS guideline recommendations regarding weight gain with ART

Tristan J. Barber, MA, MD, FRCP
Honorary Associate Professor
Institute for Global Health
University College London
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
London, United Kingdom  

Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California